- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Enables Expanded Sales Areas for VisEn's Industry Leading Fluorescence In Vivo Imaging Platforms
VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that it has signed an exclusive distribution agreement with Olympus Corporation covering sales of the company's Fluorescence Molecular Tomography (FMT) imaging systems and portfolio of in vivo near infrared fluorescence imaging probes in Asia (South Korea, Singapore, China and Taiwan).
This agreement is an expansion of an exclusive distribution agreement between the two companies covering Japan, which began in September 2006. Under the new agreement, Olympus will expand its sales territory of the VisEn products to include all key Asian markets. Olympus plans to commence sales of VisEn's products in South Korea and Singapore in January 2007, followed by China and Taiwan thereafter.
VisEn's FMT imaging system provides the industry's most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. VisEn's portfolio of biocompatible near infrared fluorescence probes are specifically tailored to enable a range of imaging readouts of key in vivo disease-associated biological processes, including angiogenesis, protease activity, vascular permeability, inflammation, cell migration and tracking, and bone remodeling. VisEn's technologies are also designed for biocompatibility and translation from pre-clinical imaging into clinical imaging in the future.
The molecular imaging systems developed and sold by Olympus are the OV100 in vivo imaging system, which can be used for a wide range of observations, from full views of small animals to the cellular level, and the IV100 in vivo laser scanning microscope, which supports direct in vivo observation of small animals. By combining VisEn's FMT system and in vivo near infrared fluorescence probes with Olympus' OV100 and IV100 molecular imaging systems, researchers can generate an unprecedented range of molecular imaging data in vivo, from the cellular and tissue levels, to the true quantification of a diverse range of biologic and molecular processes, real time within the entire body.
Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Fluorescence imaging of biologic processes and molecular activities in vivo is playing an increasingly central role today from basic research through drug development, and into clinical medicine going forward. We are very pleased to expand our partnership with Olympus in these rapidly developing new areas, and expect these programs to bring our leading technology platforms to an even broader range of customers and partners."
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and
Harvard Medical School. VisEn is developing today's highest performing
fluorescence molecular imaging technology platforms, from research through
medicine. VisEn also works directly with its partners to design ranges of
tailored probes and applications that are targeted to their specific research
areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and
has been financed by leading venture firms including Flagship Ventures and
The Bollard Group.
For more information, please click here
Bryan P. Murpy
978-745-4200 X 105
Copyright © VisEn Medical, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|